Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein
Identifieur interne : 000957 ( Istex/Corpus ); précédent : 000956; suivant : 000958Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein
Auteurs : Vladimir A. Slepushkin ; Galina V. Kornilaeva ; Sergei M. Andreev ; Maria V. Sidorova ; Anna O. Petrukhina ; Gennady R. Matsevich ; Svetlana V. Raduk ; Vladimir B. Grigoriev ; Tatiana V. Makarova ; Vladimir V. Lukashov ; Edvard V. KaramovSource :
- Virology [ 0042-6822 ] ; 1993.
Abstract
Abstract: To investigate the mechanism of action of the 22-amino-acid HIV fusion peptide on HIV infection, we studied its influence on virus adsorption and HIV-induced syncytium formation. The effect of the peptide preparations on the synthesis of viral antigens in HIV-infected cell cultures was determined by antigen capture assay, and the inhibition of proviral DNA synthesis was detected by hybridization with a HIV-specific oligonucleotide probe after PCR amplification. Fusion peptides inhibited HIV-induced syncytium formation and antigen production in lyric infected cells, and this effect was increased in conjugation with bovine serum albumin or with synthetic net-charged polymer by its C-terminus. The association of peptide with carrier by N-terminus, or with positive-charged polymer or gelatin completely abolished its effect on HIV infection. No peptide preparations influenced HIV-1 chronically infected cells. Because peptide preparations blocked the HIV-specific DNA synthesis 2 hr after infection without influencing virus adsorption and reverse transcription, we concluded that the block of infection occurred during the penetration of virions through the cell membrane. On the basis of results obtained we propose that our peptide preparations could be used for anti-HIV chemotherapy. The possibility of the existence of receptors for gp41 N-terminal region on target cell membrane is discussed.
Url:
DOI: 10.1006/viro.1993.1260
Links to Exploration step
ISTEX:3EE0927BA7F0F6F5A5B879E6A2415EE329175B71Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</title><author><name sortKey="Slepushkin, Vladimir A" sort="Slepushkin, Vladimir A" uniqKey="Slepushkin V" first="Vladimir A." last="Slepushkin">Vladimir A. Slepushkin</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Kornilaeva, Galina V" sort="Kornilaeva, Galina V" uniqKey="Kornilaeva G" first="Galina V." last="Kornilaeva">Galina V. Kornilaeva</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Andreev, Sergei M" sort="Andreev, Sergei M" uniqKey="Andreev S" first="Sergei M." last="Andreev">Sergei M. Andreev</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Sidorova, Maria V" sort="Sidorova, Maria V" uniqKey="Sidorova M" first="Maria V." last="Sidorova">Maria V. Sidorova</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Petrukhina, Anna O" sort="Petrukhina, Anna O" uniqKey="Petrukhina A" first="Anna O." last="Petrukhina">Anna O. Petrukhina</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Matsevich, Gennady R" sort="Matsevich, Gennady R" uniqKey="Matsevich G" first="Gennady R." last="Matsevich">Gennady R. Matsevich</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Raduk, Svetlana V" sort="Raduk, Svetlana V" uniqKey="Raduk S" first="Svetlana V." last="Raduk">Svetlana V. Raduk</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Grigoriev, Vladimir B" sort="Grigoriev, Vladimir B" uniqKey="Grigoriev V" first="Vladimir B." last="Grigoriev">Vladimir B. Grigoriev</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Makarova, Tatiana V" sort="Makarova, Tatiana V" uniqKey="Makarova T" first="Tatiana V." last="Makarova">Tatiana V. Makarova</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Lukashov, Vladimir V" sort="Lukashov, Vladimir V" uniqKey="Lukashov V" first="Vladimir V." last="Lukashov">Vladimir V. Lukashov</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Karamov, Edvard V" sort="Karamov, Edvard V" uniqKey="Karamov E" first="Edvard V." last="Karamov">Edvard V. Karamov</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3EE0927BA7F0F6F5A5B879E6A2415EE329175B71</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1006/viro.1993.1260</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-55FWMPWQ-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000957</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000957</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</title><author><name sortKey="Slepushkin, Vladimir A" sort="Slepushkin, Vladimir A" uniqKey="Slepushkin V" first="Vladimir A." last="Slepushkin">Vladimir A. Slepushkin</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Kornilaeva, Galina V" sort="Kornilaeva, Galina V" uniqKey="Kornilaeva G" first="Galina V." last="Kornilaeva">Galina V. Kornilaeva</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Andreev, Sergei M" sort="Andreev, Sergei M" uniqKey="Andreev S" first="Sergei M." last="Andreev">Sergei M. Andreev</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Sidorova, Maria V" sort="Sidorova, Maria V" uniqKey="Sidorova M" first="Maria V." last="Sidorova">Maria V. Sidorova</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Petrukhina, Anna O" sort="Petrukhina, Anna O" uniqKey="Petrukhina A" first="Anna O." last="Petrukhina">Anna O. Petrukhina</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Matsevich, Gennady R" sort="Matsevich, Gennady R" uniqKey="Matsevich G" first="Gennady R." last="Matsevich">Gennady R. Matsevich</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Raduk, Svetlana V" sort="Raduk, Svetlana V" uniqKey="Raduk S" first="Svetlana V." last="Raduk">Svetlana V. Raduk</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Grigoriev, Vladimir B" sort="Grigoriev, Vladimir B" uniqKey="Grigoriev V" first="Vladimir B." last="Grigoriev">Vladimir B. Grigoriev</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Makarova, Tatiana V" sort="Makarova, Tatiana V" uniqKey="Makarova T" first="Tatiana V." last="Makarova">Tatiana V. Makarova</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Lukashov, Vladimir V" sort="Lukashov, Vladimir V" uniqKey="Lukashov V" first="Vladimir V." last="Lukashov">Vladimir V. Lukashov</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author><author><name sortKey="Karamov, Edvard V" sort="Karamov, Edvard V" uniqKey="Karamov E" first="Edvard V." last="Karamov">Edvard V. Karamov</name><affiliation><mods:affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Virology</title><title level="j" type="abbrev">YVIRO</title><idno type="ISSN">0042-6822</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993">1993</date><biblScope unit="volume">194</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="294">294</biblScope><biblScope unit="page" to="301">301</biblScope></imprint><idno type="ISSN">0042-6822</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0042-6822</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: To investigate the mechanism of action of the 22-amino-acid HIV fusion peptide on HIV infection, we studied its influence on virus adsorption and HIV-induced syncytium formation. The effect of the peptide preparations on the synthesis of viral antigens in HIV-infected cell cultures was determined by antigen capture assay, and the inhibition of proviral DNA synthesis was detected by hybridization with a HIV-specific oligonucleotide probe after PCR amplification. Fusion peptides inhibited HIV-induced syncytium formation and antigen production in lyric infected cells, and this effect was increased in conjugation with bovine serum albumin or with synthetic net-charged polymer by its C-terminus. The association of peptide with carrier by N-terminus, or with positive-charged polymer or gelatin completely abolished its effect on HIV infection. No peptide preparations influenced HIV-1 chronically infected cells. Because peptide preparations blocked the HIV-specific DNA synthesis 2 hr after infection without influencing virus adsorption and reverse transcription, we concluded that the block of infection occurred during the penetration of virions through the cell membrane. On the basis of results obtained we propose that our peptide preparations could be used for anti-HIV chemotherapy. The possibility of the existence of receptors for gp41 N-terminal region on target cell membrane is discussed.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Vladimir A. Slepushkin</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Galina V. Kornilaeva</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Sergei M. Andreev</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Maria V. Sidorova</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Anna O. Petrukhina</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Gennady R. Matsevich</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Svetlana V. Raduk</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Vladimir B. Grigoriev</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Tatiana V. Makarova</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Vladimir V. Lukashov</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item><json:item><name>Edvard V. Karamov</name><affiliations><json:string>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</json:string></affiliations></json:item></author><arkIstex>ark:/67375/6H6-55FWMPWQ-1</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: To investigate the mechanism of action of the 22-amino-acid HIV fusion peptide on HIV infection, we studied its influence on virus adsorption and HIV-induced syncytium formation. The effect of the peptide preparations on the synthesis of viral antigens in HIV-infected cell cultures was determined by antigen capture assay, and the inhibition of proviral DNA synthesis was detected by hybridization with a HIV-specific oligonucleotide probe after PCR amplification. Fusion peptides inhibited HIV-induced syncytium formation and antigen production in lyric infected cells, and this effect was increased in conjugation with bovine serum albumin or with synthetic net-charged polymer by its C-terminus. The association of peptide with carrier by N-terminus, or with positive-charged polymer or gelatin completely abolished its effect on HIV infection. No peptide preparations influenced HIV-1 chronically infected cells. Because peptide preparations blocked the HIV-specific DNA synthesis 2 hr after infection without influencing virus adsorption and reverse transcription, we concluded that the block of infection occurred during the penetration of virions through the cell membrane. On the basis of results obtained we propose that our peptide preparations could be used for anti-HIV chemotherapy. The possibility of the existence of receptors for gp41 N-terminal region on target cell membrane is discussed.</abstract><qualityIndicators><score>4.45</score><pdfWordCount>0</pdfWordCount><pdfCharCount>0</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>614 x 804 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>200</abstractWordCount><abstractCharCount>1417</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</title><pmid><json:string>7683157</json:string></pmid><pii><json:string>S0042-6822(83)71260-2</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Virology</title><language><json:string>unknown</json:string></language><publicationDate>1993</publicationDate><issn><json:string>0042-6822</json:string></issn><pii><json:string>S0042-6822(00)X0177-8</json:string></pii><volume>194</volume><issue>1</issue><pages><first>294</first><last>301</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-55FWMPWQ-1</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - virology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Virology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1006/viro.1993.1260</json:string></doi><id>3EE0927BA7F0F6F5A5B879E6A2415EE329175B71</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-55FWMPWQ-1/fulltext.pdf</uri></json:item><json:item><extension>ocr</extension><original>false</original><mimetype>text/ocr</mimetype><quality><totalToken>6081</totalToken><correct>5251</correct><rate>79.56260324565524</rate><misspelled>812</misspelled></quality><langDetect><reliable>true</reliable><languages><json:item><score>916</score><code>en</code><name>ENGLISH</name><percent>98</percent></json:item></languages></langDetect><uri>https://api.istex.fr/ark:/67375/6H6-55FWMPWQ-1/fulltext.ocr</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-55FWMPWQ-1/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-55FWMPWQ-1/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>©1993 Academic Press</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</p></availability><date>1993</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Regular Article</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</title><author xml:id="author-0000"><persName><forename type="first">Vladimir A.</forename><surname>Slepushkin</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Galina V.</forename><surname>Kornilaeva</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Sergei M.</forename><surname>Andreev</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Maria V.</forename><surname>Sidorova</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Anna O.</forename><surname>Petrukhina</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Gennady R.</forename><surname>Matsevich</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Svetlana V.</forename><surname>Raduk</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Vladimir B.</forename><surname>Grigoriev</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0008"><persName><forename type="first">Tatiana V.</forename><surname>Makarova</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0009"><persName><forename type="first">Vladimir V.</forename><surname>Lukashov</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><author xml:id="author-0010"><persName><forename type="first">Edvard V.</forename><surname>Karamov</surname></persName><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation></author><idno type="istex">3EE0927BA7F0F6F5A5B879E6A2415EE329175B71</idno><idno type="ark">ark:/67375/6H6-55FWMPWQ-1</idno><idno type="DOI">10.1006/viro.1993.1260</idno><idno type="PII">S0042-6822(83)71260-2</idno></analytic><monogr><title level="j">Virology</title><title level="j" type="abbrev">YVIRO</title><idno type="pISSN">0042-6822</idno><idno type="PII">S0042-6822(00)X0177-8</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993"></date><biblScope unit="volume">194</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="294">294</biblScope><biblScope unit="page" to="301">301</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: To investigate the mechanism of action of the 22-amino-acid HIV fusion peptide on HIV infection, we studied its influence on virus adsorption and HIV-induced syncytium formation. The effect of the peptide preparations on the synthesis of viral antigens in HIV-infected cell cultures was determined by antigen capture assay, and the inhibition of proviral DNA synthesis was detected by hybridization with a HIV-specific oligonucleotide probe after PCR amplification. Fusion peptides inhibited HIV-induced syncytium formation and antigen production in lyric infected cells, and this effect was increased in conjugation with bovine serum albumin or with synthetic net-charged polymer by its C-terminus. The association of peptide with carrier by N-terminus, or with positive-charged polymer or gelatin completely abolished its effect on HIV infection. No peptide preparations influenced HIV-1 chronically infected cells. Because peptide preparations blocked the HIV-specific DNA synthesis 2 hr after infection without influencing virus adsorption and reverse transcription, we concluded that the block of infection occurred during the penetration of virions through the cell membrane. On the basis of results obtained we propose that our peptide preparations could be used for anti-HIV chemotherapy. The possibility of the existence of receptors for gp41 N-terminal region on target cell membrane is discussed.</p></abstract></profileDesc><revisionDesc><change when="1993">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-55FWMPWQ-1/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier converted-article found"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>YVIRO</jid><aid>71260</aid><ce:pii>S0042-6822(83)71260-2</ce:pii><ce:doi>10.1006/viro.1993.1260</ce:doi><ce:copyright type="full-transfer" year="1993">Academic Press</ce:copyright></item-info><head><ce:dochead><ce:textfn>Regular Article</ce:textfn></ce:dochead><ce:title>Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</ce:title><ce:author-group><ce:author><ce:given-name>Vladimir A.</ce:given-name><ce:surname>Slepushkin</ce:surname></ce:author><ce:author><ce:given-name>Galina V.</ce:given-name><ce:surname>Kornilaeva</ce:surname></ce:author><ce:author><ce:given-name>Sergei M.</ce:given-name><ce:surname>Andreev</ce:surname></ce:author><ce:author><ce:given-name>Maria V.</ce:given-name><ce:surname>Sidorova</ce:surname></ce:author><ce:author><ce:given-name>Anna O.</ce:given-name><ce:surname>Petrukhina</ce:surname></ce:author><ce:author><ce:given-name>Gennady R.</ce:given-name><ce:surname>Matsevich</ce:surname></ce:author><ce:author><ce:given-name>Svetlana V.</ce:given-name><ce:surname>Raduk</ce:surname></ce:author><ce:author><ce:given-name>Vladimir B.</ce:given-name><ce:surname>Grigoriev</ce:surname></ce:author><ce:author><ce:given-name>Tatiana V.</ce:given-name><ce:surname>Makarova</ce:surname></ce:author><ce:author><ce:given-name>Vladimir V.</ce:given-name><ce:surname>Lukashov</ce:surname></ce:author><ce:author><ce:given-name>Edvard V.</ce:given-name><ce:surname>Karamov</ce:surname></ce:author><ce:affiliation><ce:textfn>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1<ce:sup>st</ce:sup> Dubrovskaya St., 109088 Moscow, Russia</ce:textfn></ce:affiliation></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>To investigate the mechanism of action of the 22-amino-acid HIV fusion peptide on HIV infection, we studied its influence on virus adsorption and HIV-induced syncytium formation. The effect of the peptide preparations on the synthesis of viral antigens in HIV-infected cell cultures was determined by antigen capture assay, and the inhibition of proviral DNA synthesis was detected by hybridization with a HIV-specific oligonucleotide probe after PCR amplification. Fusion peptides inhibited HIV-induced syncytium formation and antigen production in lyric infected cells, and this effect was increased in conjugation with bovine serum albumin or with synthetic net-charged polymer by its C-terminus. The association of peptide with carrier by N-terminus, or with positive-charged polymer or gelatin completely abolished its effect on HIV infection. No peptide preparations influenced HIV-1 chronically infected cells. Because peptide preparations blocked the HIV-specific DNA synthesis 2 hr after infection without influencing virus adsorption and reverse transcription, we concluded that the block of infection occurred during the penetration of virions through the cell membrane. On the basis of results obtained we propose that our peptide preparations could be used for anti-HIV chemotherapy. The possibility of the existence of receptors for gp41 N-terminal region on target cell membrane is discussed.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein</title></titleInfo><name type="personal"><namePart type="given">Vladimir A.</namePart><namePart type="family">Slepushkin</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Galina V.</namePart><namePart type="family">Kornilaeva</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sergei M.</namePart><namePart type="family">Andreev</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maria V.</namePart><namePart type="family">Sidorova</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anna O.</namePart><namePart type="family">Petrukhina</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gennady R.</namePart><namePart type="family">Matsevich</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Svetlana V.</namePart><namePart type="family">Raduk</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vladimir B.</namePart><namePart type="family">Grigoriev</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tatiana V.</namePart><namePart type="family">Makarova</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vladimir V.</namePart><namePart type="family">Lukashov</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Edvard V.</namePart><namePart type="family">Karamov</namePart><affiliation>D. I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, 16 Gamaleya St., 123098 Moscow, Russia; Institute of Immunology, Ministry of Public Health of Russia, 24/2 Kashirskoe Sh., 115478 Moscow, Russia; and Research Institute of Viral Preparations, Russian Academy of Medical Sciences, 15 1st Dubrovskaya St., 109088 Moscow, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: To investigate the mechanism of action of the 22-amino-acid HIV fusion peptide on HIV infection, we studied its influence on virus adsorption and HIV-induced syncytium formation. The effect of the peptide preparations on the synthesis of viral antigens in HIV-infected cell cultures was determined by antigen capture assay, and the inhibition of proviral DNA synthesis was detected by hybridization with a HIV-specific oligonucleotide probe after PCR amplification. Fusion peptides inhibited HIV-induced syncytium formation and antigen production in lyric infected cells, and this effect was increased in conjugation with bovine serum albumin or with synthetic net-charged polymer by its C-terminus. The association of peptide with carrier by N-terminus, or with positive-charged polymer or gelatin completely abolished its effect on HIV infection. No peptide preparations influenced HIV-1 chronically infected cells. Because peptide preparations blocked the HIV-specific DNA synthesis 2 hr after infection without influencing virus adsorption and reverse transcription, we concluded that the block of infection occurred during the penetration of virions through the cell membrane. On the basis of results obtained we propose that our peptide preparations could be used for anti-HIV chemotherapy. The possibility of the existence of receptors for gp41 N-terminal region on target cell membrane is discussed.</abstract><note type="content">Section title: Regular Article</note><relatedItem type="host"><titleInfo><title>Virology</title></titleInfo><titleInfo type="abbreviated"><title>YVIRO</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued></originInfo><identifier type="ISSN">0042-6822</identifier><identifier type="PII">S0042-6822(00)X0177-8</identifier><part><date>1993</date><detail type="volume"><number>194</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1</start><end>432</end></extent><extent unit="pages"><start>294</start><end>301</end></extent></part></relatedItem><identifier type="istex">3EE0927BA7F0F6F5A5B879E6A2415EE329175B71</identifier><identifier type="ark">ark:/67375/6H6-55FWMPWQ-1</identifier><identifier type="DOI">10.1006/viro.1993.1260</identifier><identifier type="PII">S0042-6822(83)71260-2</identifier><accessCondition type="use and reproduction" contentType="copyright">©1993 Academic Press</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>Academic Press, ©1993</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-55FWMPWQ-1/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000957 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000957 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3EE0927BA7F0F6F5A5B879E6A2415EE329175B71
|texte= Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Penetration into Target Cells by Synthetic Peptides Mimicking the N-Terminus of the HIV-1 Transmembrane Glycoprotein
}}
| This area was generated with Dilib version V0.6.33. |  |